PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32652973-0	2020	Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial.	Metformin	0-9	insulin like growth factor binding protein 1	Homo sapiens	93-114	
32652973-2	2020	We studied whether metformin treatment has favorable or unfavorable effects on inflammatory markers and insulin-like growth factor-binding protein 1 (IGFBP-1) in GDM patients compared with insulin, and whether these markers associate with major maternal or fetal clinical outcomes.	Metformin	19-28	insulin like growth factor binding protein 1	Homo sapiens	104-148	
32652973-2	2020	We studied whether metformin treatment has favorable or unfavorable effects on inflammatory markers and insulin-like growth factor-binding protein 1 (IGFBP-1) in GDM patients compared with insulin, and whether these markers associate with major maternal or fetal clinical outcomes.	Metformin	19-28	insulin like growth factor binding protein 1	Homo sapiens	150-157	
32652973-7	2020	GlycA (p = 0.02) and non-phosphorylated IGFBP-1 (p = 0.008) increased more in patients treated with metformin than those treated with insulin.	Metformin	100-109	insulin like growth factor binding protein 1	Homo sapiens	40-47	
32652973-9	2020	CONCLUSIONS: Metformin had beneficial effects on maternal serum IGFBP-1 concentrations compared to insulin, as increased IGFBP-1 related to lower total and late pregnancy maternal weight gain.	Metformin	13-22	insulin like growth factor binding protein 1	Homo sapiens	64-71